Bianca Muñiz, a three-time cancer survivor first diagnosed at age 11, shared her powerful story on International Childhood ...

"I feel like I have a responsibility to scream and shout loudly about it and say 'hey, this is killing women in Australia'," ...

Ovarian cancer is the sixth most common cancer in women in the UK but the symptoms can be quite subtle, often leaving to a ...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. Suitable for ...

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

Researchers at the University of California San Diego are hoping to drastically shorten the time between a cancer diagnosis ...

A simple blood test could soon predict which ovarian cancer patients will stop responding to their treatment, paving the way ...

University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

Penn Ovarian Cancer Research Center and Basser Center for BRCA, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States ...